Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
GABAPENTIN
Profind Wholesale Ltd.
300 Milligram
Capsules Hard
2009-07-24
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PPA1500/029/002 Case No: 2083742 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to PROFIND WHOLESALE LTD. UNIT 625, KILSHANE AVENUE, NORTHWEST BUSINESS PARK, DUBLIN 15, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product NEURONTIN 300 MG HARD CAPSULES the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 28/07/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/07/2010_ _CRN 2083742_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Neurontin 300 mg Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 300 mg hard capsule contains 300 mg of gabapentin. EXCIPIENTS: Each 300 mg hard capsule contains 41 mg lactose (as monohydrate) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard _Product imported from the UK:_ A two-piece, yellow opaque hard gelatin capsule, imprinted with ‘Neurontin 300mg’ and “PD” and containing a white to off-white powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Epilepsy Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary g Lees het volledige document